Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19 to block viral entry and decrease viral replication.
Description: The primary endpoint is a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital discharge
Measure: All Cause-death or invasive mechanical ventilation Time: 28 daysDescription: Log transformed levels of Lactate dehydrogenase (LDH) at day 5 as a surrogate marker for organ damage (powered secondary endpoint
Measure: LDH level Time: Day 5Description: 28-day mortality (all cause-death)
Measure: Mortality Time: 28 daysDescription: Ventilator-free days (VFD) up to 28 days or hospital discharge
Measure: VFD Time: 28 daysDescription: Time to death (all causes)
Measure: Time to death Time: 28 days